Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Stockholders' Equity

v3.22.1
Condensed Consolidated Statement of Stockholders' Equity - USD ($)
$ in Thousands
Total
Common Stock [Member]
Additional Paid-in Capital [Member]
Accumulated Other Comprehensive Loss [Member]
Accumulated Deficit [Member]
Balance at beginning of period at Dec. 31, 2020 $ 142,706 $ 7 $ 819,549 $ 8 $ (676,858)
Balance at beginning of period (in shares) at Dec. 31, 2020   68,946,092      
Stock-based compensation expense 2,505   2,505    
Net loss (17,551)       (17,551)
Net unrealized gain (loss) on marketable securities (14)     (14)  
Balance at end of period at Mar. 31, 2021 127,646 $ 7 822,054 (6) (694,409)
Balance at end of period (in shares) at Mar. 31, 2021   68,946,092      
Balance at beginning of period at Dec. 31, 2021 132,937 $ 8 899,798 (13) (766,856)
Balance at beginning of period (in shares) at Dec. 31, 2021   84,677,939      
Issuance costs related to issuance of common stock and pre funded warrants shares (Shares)   0      
Issuance costs related to issuance of common stock and pre funded warrants 5   5    
Stock-based compensation expense 2,414   2,414    
Net loss (27,769)       (27,769)
Net unrealized gain (loss) on marketable securities (206)     (206)  
Balance at end of period at Mar. 31, 2022 $ 107,381 $ 8 $ 902,217 $ (219) $ (794,625)
Balance at end of period (in shares) at Mar. 31, 2022   84,677,939